TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX) will host a virtual key opinion leader event on December 8, 2025 at 8:00 a.m. ET to discuss updated data from the ALLOHA™ Phase 1 trial and the market opportunity for its heme program.

The event will review a poster presented at the 67th ASH Annual Meeting, including two-year relapse data from initial patients in the ALLOHA trial of TSC-101 in heme malignancy patients undergoing allogeneic HCT, the company’s newly implemented commercial-ready manufacturing process, and plans for a pivotal trial slated to start in Q2 2026. A replay will be available on the company’s Events and Presentations page.

News Market Reaction

+7.12%

2 alerts

+7.12% News Effect

+$4M Valuation Impact

$54M Market Cap

1K Volume

On the day this news was published, TCRX gained 7.12%, reflecting a notable positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $54M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Trial phase: Phase 1 Follow-up duration: Two-year relapse data Trial start target: Q2 2026 +5 more

8 metrics

Trial phase Phase 1 ALLOHA trial of TSC-101 in heme malignancies

Follow-up duration Two-year relapse data Initial ALLOHA Phase 1 patients post allogeneic HCT

Trial start target Q2 2026 Planned start of pivotal TSC-101 trial

Event date December 8, 2025 Virtual KOL event discussing ALLOHA updates

Event time 8:00 a.m. ET Start time of virtual KOL event

Current price $1.07 Pre‑news trading level vs 52‑week range

52-week high $4.8496 Upper end of 52-week range before this news

52-week low $0.91 Lower end of 52-week range before this news

Market Reality Check

Price: $0.9614 Vol: Volume 262,549 is below t...

low vol

$0.9614 Last Close

Volume Volume 262,549 is below the 20-day average of 854,496 ahead of the KOL event. low

Technical Shares at $1.07 are trading below the 200-day MA of $1.62, well under the $4.85 52-week high.

Peers on Argus

Peers show mixed moves, with names like MEIP and MGNX up while ANIX and HLVX are...

1 Down

Peers show mixed moves, with names like MEIP and MGNX up while ANIX and HLVX are down. Momentum scanner only flagged CRBP moving down, suggesting today’s setup for TCRX is stock-specific rather than a broad biotech move.

Historical Context

5 past events · Latest: Dec 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 06	Clinical data update	Positive	-7.4%	Updated ALLOHA Phase 1 data with improved survival versus control arm.
Dec 03	KOL event announcement	Positive	+7.1%	Announcement of virtual KOL event to discuss ALLOHA data and market.
Nov 12	Earnings and update	Neutral	-2.5%	Q3 2025 results plus strategic focus on heme and ALLOHA update timing.
Nov 05	Conference participation	Neutral	+1.3%	Participation in Guggenheim healthcare conference with webcast access.
Nov 03	Strategic shift	Negative	-36.1%	Pivotal design for TSC-101 plus workforce reduction and cost-saving measures.

Pattern Detected

Positive ALLOHA clinical updates previously saw one notable divergence, with shares declining despite favorable data, but other events have generally aligned with their tone.

Recent Company History

Over the last two months, TScan has focused on its heme program and TSC‑101. On Nov 3, it aligned with the FDA on a pivotal design, cut workforce by ~30%, and extended cash runway into H2 2027, which coincided with a -36.08% move. Subsequent Q3 results on Nov 12 highlighted $2.5M revenue and updated ALLOHA data plans. The current KOL event follows positive ALLOHA Phase 1 data presented at ASH on Dec 6, which previously led to a -7.41% reaction despite improved outcomes.

Market Pulse Summary

The stock moved +7.1% in the session following this news. A strong positive reaction aligns with gro...

Analysis

The stock moved +7.1% in the session following this news. A strong positive reaction aligns with growing focus on TScan’s heme program and ALLOHA data. Prior positive trial updates sometimes saw selling, as with the -7.41% move after ASH data, so sustainability depended on how investors viewed long-term execution. With shares well below the $4.85 52-week high and below the $1.62 200-day MA, earlier dilution or execution concerns could still have limited follow‑through.

Key Terms

key opinion leader, phase 1, allogeneic hematopoietic cell transplantation, hematopoietic cell transplantation, +1 more

5 terms

key opinion leader technical

"will host a virtual key opinion leader (KOL) event to discuss updated data"

A key opinion leader is an individual whose insights, expertise, or influence significantly shape the opinions and decisions of others within a particular field or community. For investors, they are like trusted guides whose views can impact market trends or perceptions, making their perspectives important to watch. Their influence often stems from experience, reputation, or widespread respect among peers.

phase 1 medical

"updated data from the ALLOHA™ Phase 1 trial being presented at the 67th"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

allogeneic hematopoietic cell transplantation medical

"patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation (HCT)"

Allogeneic hematopoietic cell transplantation is a medical procedure that replaces a patient’s blood-forming stem cells with healthy stem cells taken from a genetically matched donor. Think of it as replanting a damaged garden with soil and seeds from another plot to regrow a healthy crop; it can cure certain blood cancers and immune disorders but carries risks, complex logistics and high costs, so outcomes and supply issues can strongly affect clinical value, regulatory decisions and investor returns.

hematopoietic cell transplantation medical

"heme malignancies undergoing allogeneic hematopoietic cell transplantation (HCT)"

A medical procedure that replaces a patient’s blood‑forming stem cells with healthy cells from the patient or a donor to rebuild the immune system and restore blood production. Think of it as replanting a damaged garden with new seeds so healthy plants can grow again; it matters to investors because the procedure’s demand, clinical success, regulatory approvals, supply chain for donor material or cell products, and treatment costs directly affect the revenues and risks of drug makers, medical device firms, hospitals and insurers.

commercial-ready manufacturing process technical

"its improved commercial-ready manufacturing process that has recently been implemented"

A commercial-ready manufacturing process is a fully developed, validated, and repeatable method for producing a product at the volumes, quality, and cost required for broad market sale. For investors, it indicates the company can reliably make and deliver goods, meet regulatory and quality standards, control production costs, and scale revenue—like turning a home recipe into a factory line that runs consistently and at predictable expense.

AI-generated analysis. Not financial advice.

WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated data from the ALLOHA™ Phase 1 trial being presented at the 67^th American Society of Hematology (ASH) Annual Meeting and Exposition and the future market opportunity for its heme program. The virtual event will take place on Monday, December 8, at 8:00 a.m. ET.

The event will provide an in-depth review of the poster presented at the ASH Annual Meeting, including two-year relapse data on initial patients from TScan’s ongoing ALLOHA Phase 1 trial evaluating TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). The Company will discuss its improved commercial-ready manufacturing process that has recently been implemented in the ALLOHA Phase 1 trial and will be used in the upcoming pivotal trial scheduled to start in the second quarter of 2026. The Company will also review the unmet medical need and potential market opportunity for TSC-101 and follow-on product candidates.

Featured speakers include:

• Ran Reshef, M.D., M.Sc., Director of Translational Research, Blood and Marrow Transplantation Program, Director of the Cell Therapy Program, Columbia University Irving Medical Center
  
• Gavin MacBeath, Ph.D., Chief Executive Officer, TScan Therapeutics
  
• Stephen Camiolo, Senior Vice President, Market Access, TScan Therapeutics
  

Registration for the live event can be found here. A replay will be made available on the “Events and Presentations” section of the Company’s website at ir.tscan.com.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidate is in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA^™ Phase 1 heme trial). The Company has developed multiple TCR-T therapy candidates for solid tumors and is currently developing methods for in vivo engineering using these candidates. The Company is also applying their TargetScan platform to discover novel targets in various T cell-mediated autoimmune disorders.

Contacts

Troy Neubecker
TScan Therapeutics, Inc.
Investor Relations
857-399-9517
tneubecker@tscan.com

Melissa Forst
Argot Partners
212-600-1902
TScan@argotpartners.com

FAQ

When will TScan (TCRX) host the virtual KOL event to discuss ALLOHA Phase 1 updates?

The virtual event will be held on December 8, 2025 at 8:00 a.m. ET.

What ALLOHA Phase 1 data will TScan (TCRX) review at the December 8, 2025 event?

The company will review the ASH poster including two-year relapse data from initial ALLOHA patients treated with TSC-101.

How will TScan (TCRX) use its new manufacturing process discussed at the KOL event?

TScan said the improved commercial-ready manufacturing process is implemented in ALLOHA and will be used in the pivotal trial starting Q2 2026.

Who are the featured speakers for TScan's December 8, 2025 virtual event?

Featured speakers include Ran Reshef, M.D., Gavin MacBeath, Ph.D., and Stephen Camiolo.

Where can investors access the TScan (TCRX) live event and replay for the ALLOHA update?

Registration is available via the company website and a replay will be posted in the Events and Presentations section at ir.tscan.com.

What key development timeline did TScan (TCRX) disclose for TSC-101 in heme malignancies?

TScan indicated the pivotal trial is scheduled to start in Q2 2026.